Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Long-Term Investments (2019 - 2022)

Historic Long-Term Investments for Sutro Biopharma (STRO) over the last 4 years, with Q1 2022 value amounting to $20.7 million.

  • Sutro Biopharma's Long-Term Investments fell 7225.76% to $20.7 million in Q1 2022 from the same period last year, while for Mar 2022 it was $20.7 million, marking a year-over-year decrease of 7225.76%. This contributed to the annual value of $68.8 million for FY2021, which is N/A changed from last year.
  • Latest data reveals that Sutro Biopharma reported Long-Term Investments of $20.7 million as of Q1 2022, which was down 7225.76% from $68.8 million recorded in Q4 2021.
  • Sutro Biopharma's Long-Term Investments' 5-year high stood at $74.6 million during Q1 2021, with a 5-year trough of $5.6 million in Q2 2020.
  • Moreover, its 4-year median value for Long-Term Investments was $20.7 million (2022), whereas its average is $34.4 million.
  • Its Long-Term Investments has fluctuated over the past 5 years, first soared by 96261.73% in 2021, then tumbled by 7225.76% in 2022.
  • Sutro Biopharma's Long-Term Investments (Quarter) stood at $15.6 million in 2019, then crashed by 63.82% to $5.6 million in 2020, then surged by 1118.35% to $68.8 million in 2021, then plummeted by 69.91% to $20.7 million in 2022.
  • Its Long-Term Investments was $20.7 million in Q1 2022, compared to $68.8 million in Q4 2021 and $64.3 million in Q3 2021.